BCYC - Bicycle Therapeutics plc News

Sectors

BCYC

Bicycle Therapeutics plc

4.12

2 x 3.00

2 x 5.33

bid

ask

0.08

2.02%

03:06 PM

timesize

Ytd	-41.88%
1y	-44.24%

4.12

day range

4.32

3.75

52 week range

9.16

Open	4.21	Prev Close	4.20	Low	4.12	High	4.32	Mkt Cap	288.02M
Vol	137.12K	Avg Vol	424.05K	EPS	-2.73	P/E	N/A	Forward P/E	-3.09
Beta	1.55	Short Ratio	14.44	Inst. Own	92.44%	Dividend	N/A	Div Yield	N/A
Ex Div Date	N/A	Earning	10-29	50-d Avg	4.13	200-d Avg	5.25	1yr Est	29.55

BCYC News

pymnts.com

Visa Inks $2.4 Billion Deal to Acquire Fraud Prevention Firm BioCatch

Visa is set to acquire Israel-based fraud intelligence company BioCatch for $2.4 billion. The all-ca

benzinga.com

Needham Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $14

Needham analyst Ami Fadia maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and lowers the

benzinga.com

Bicycle Therapeutics Q2 EPS $(0.72) Misses $(0.59) Estimate, Sales $629.000K Miss $4.221M Estimate

Bicycle Therapeutics (NASDAQ:BCYC) reported quarterly losses of $(0.72) per share which missed the a

businesswire.com

Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceuti

benzinga.com

Bicycle Therapeutics' Zelenectide Pevedotin Plus Pembrolizumab Shows SOC-Comparable Response And Imp

In the dose optimization stage of the randomized Phase 2 trial (Duravelo-2), zelenectide pevedotin a

businesswire.com

Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceuti

benzinga.com

Bicycle Therapeutics Q1 EPS $(0.87) Misses $(0.73) Estimate, Sales $887.000K Miss $7.267M Estimate

Bicycle Therapeutics (NASDAQ:BCYC) reported quarterly losses of $(0.87) per share which missed the a

businesswire.com

Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceuti

benzinga.com

Bicycle Therapeutics Reveals Oral and Poster Presentations At The 2026 ASCO Annual Meeting

Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated

businesswire.com

Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceuti

benzinga.com

Bicycle Therapeutics Issues Updates From Its EphA2 Pipeline At The American Association for Cancer R

AACR Annual Meeting 2026 Data HighlightsNuzefatide pevedotin (nuzefatide), formerly BT5528, a potent

businesswire.com

Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual M

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceuti

zacks.com

Wall Street Analysts Believe Bicycle Therapeutics (BCYC) Could Rally 137.88%: Here's is How to Trade

The mean of analysts' price targets for Bicycle Therapeutics (BCYC) points to a 137.9% upside in the

benzinga.com

Morgan Stanley Maintains Equal-Weight on Bicycle Therapeutics, Lowers Price Target to $12

Morgan Stanley analyst Jeffrey Hung maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Equal-Wei

defenseworld.net

Bicycle Therapeutics (NASDAQ:BCYC) CEO Kevin Lee Sells 5,967 Shares

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ: BCYC - Get Free Report) CEO Kevin Lee sold 5,967 sha

defenseworld.net

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Rating of “Hold” from Analys

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ: BCYC - Get Free Report) has received a consensus rat

zacks.com

After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Bicycle Therapeutics (BCYC)

Bicycle Therapeutics (BCYC) is technically in oversold territory now, so the heavy selling pressure

zacks.com

Bicycle Therapeutics (BCYC) Loses 19.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Co

Bicycle Therapeutics (BCYC) is technically in oversold territory now, so the heavy selling pressure

benzinga.com

Oppenheimer Maintains Outperform on Bicycle Therapeutics, Lowers Price Target to $36

Oppenheimer analyst Jay Olson maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Outperform and

benzinga.com

RBC Capital Maintains Sector Perform on Bicycle Therapeutics, Lowers Price Target to $7

RBC Capital analyst Leonid Timashev maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Sector Pe

benzinga.com

Citizens Maintains Market Outperform on Bicycle Therapeutics, Lowers Price Target to $8

Citizens analyst Brett Knoblauch maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Market Outpe

businesswire.com

Bicycle Therapeutics Announces Oral and Poster Presentations at the AACR Annual Meeting 2026

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceuti

benzinga.com

Needham Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $15

Needham analyst Ami Fadia maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and lowers the

benzinga.com

Bicycle Therapeutics Q4 EPS $(0.29) Beats $(1.00) Estimate, Sales $47.955M Up YoY From $3.708M

Bicycle Therapeutics (NASDAQ:BCYC) reported quarterly losses of $(0.29) per share which beat the ana

businesswire.com

Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financia

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceuti

defenseworld.net

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Recommendation of “Moderate Buy

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ: BCYC - Get Free Report) has earned an average rating

benzinga.com

Bicycle Therapeutics Announces Key Leadership Transitions, Appoints Travis Thompson As CFO and Micha

Travis Thompson appointed chief financial officer; to succeed Alethia YoungMichael Method, M.D., MPH

businesswire.com

Bicycle Therapeutics Announces Leadership Transitions for Next Phase of Innovation Across Oncology P

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceuti

benzinga.com

Bicycle Therapeutics Outlines 2026 Strategy With Duravelo-2 Regulatory Update Expected In 1Q 2026, R

Dose selection from Phase 2/3 Duravelo-2 trial and update on potential approval pathway expected in

businesswire.com

Bicycle Therapeutics Highlights 2025 Accomplishments and Strategic Priorities for 2026

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceuti

defenseworld.net

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Rating of “Hold” from Brokerag

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ: BCYC - Get Free Report) has received a consensus rec

benzinga.com

Bicycle Therapeutics Secures Long-Term Nuclear And Industry Partnerships To Support 212Pb Radiopharm

Execution of a 15-year contract including an option to renew with UK Nuclear Decommissioning Authori

businesswire.com

Bicycle Therapeutics Establishes Multiple Strategic Partnerships to Create End-to-End Supply Chain t

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceuti

prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bicycle Therapeutic

NEW YORK , Dec. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor

defenseworld.net

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Rating of “Hold” from Broker

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ: BCYC - Get Free Report) has received an average reco

benzinga.com

Truist Securities Initiates Coverage On Bicycle Therapeutics with Hold Rating, Announces Price Targe

Truist Securities analyst Gregory Renza initiates coverage on Bicycle Therapeutics (NASDAQ:BCYC)

benzinga.com

Citizens Maintains Market Outperform on Bicycle Therapeutics, Raises Price Target to $12

Citizens analyst Reni Benjamin maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Market Outperf

benzinga.com

This Itron Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

benzinga.com

RBC Capital Downgrades Bicycle Therapeutics to Sector Perform, Lowers Price Target to $11

RBC Capital analyst Leonid Timashev downgrades Bicycle Therapeutics (NASDAQ:BCYC) from Outperform

benzinga.com

Bicycle Therapeutics Q3 EPS $(0.85) Beats $(1.09) Estimate, Sales $11.734M Beat $7.333M Estimate

Bicycle Therapeutics (NASDAQ:BCYC) reported quarterly losses of $(0.85) per share which beat the ana

benzinga.com

4 Analysts Assess Bicycle Therapeutics: What You Need To Know

benzinga.com

JMP Securities Maintains Market Outperform on Bicycle Therapeutics, Lowers Price Target to $10

JMP Securities analyst Reni J. Benjamin maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Marke

benzinga.com

Morgan Stanley Maintains Equal-Weight on Bicycle Therapeutics, Lowers Price Target to $13

Morgan Stanley analyst Jeffrey Hung maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Equal-Wei

benzinga.com

Oppenheimer Maintains Outperform on Bicycle Therapeutics, Lowers Price Target to $44

Oppenheimer analyst Jay Olson maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Outperform and

benzinga.com

Demystifying Bicycle Therapeutics: Insights From 7 Analyst Reviews

benzinga.com

RBC Capital Maintains Outperform on Bicycle Therapeutics, Lowers Price Target to $25

RBC Capital analyst Leonid Timashev maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Outperfor

benzinga.com

Morgan Stanley Maintains Equal-Weight on Bicycle Therapeutics, Raises Price Target to $17

Morgan Stanley analyst Jeffrey Hung maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Equal-Wei

benzinga.com

RBC Capital Maintains Outperform on Bicycle Therapeutics, Lowers Price Target to $32

RBC Capital analyst Gregory Renza maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Outperform

benzinga.com

B. Riley Securities Maintains Neutral on Bicycle Therapeutics, Lowers Price Target to $14

B. Riley Securities analyst Kalpit Patel maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Neut

benzinga.com

JMP Securities Maintains Market Outperform on Bicycle Therapeutics, Lowers Price Target to $22

JMP Securities analyst Reni Benjamin maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Market O